Does The Street Have Integra LifeSciences Holdings Figured Out?
Integra LifeSciences Holdings (NAS: IART) is expected to report Q3 earnings on Oct. 24. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Integra LifeSciences Holdings's revenues will grow 4.6% and EPS will wither 0.0%.
The average estimate for revenue is $211.4 million. On the bottom line, the average EPS estimate is $0.77.
Last quarter, Integra LifeSciences Holdings tallied revenue of $210.2 million. GAAP reported sales were 8.7% higher than the prior-year quarter's $193.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.74. GAAP EPS of $0.30 for Q2 were much higher than the prior-year quarter's $0.02 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 64.5%, 40 basis points better than the prior-year quarter. Operating margin was 13.0%, 170 basis points worse than the prior-year quarter. Net margin was 4.1%, 370 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $834.5 million. The average EPS estimate is $3.04.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 158 members out of 170 rating the stock outperform, and 12 members rating it underperform. Among 54 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 53 give Integra LifeSciences Holdings a green thumbs-up, and one give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Integra LifeSciences Holdings is outperform, with an average price target of $42.31.
- Add Integra LifeSciences Holdings to My Watchlist.
The article Does The Street Have Integra LifeSciences Holdings Figured Out? originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend Integra LifeSciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.